Traditional business intelligence has a dangerous blind spot. This guide explains why US life science leaders need external signal monitoring to track regulatory, political, and supply chain risks before they become crises.
9 articles tagged regulatory intelligence.
Traditional business intelligence has a dangerous blind spot. This guide explains why US life science leaders need external signal monitoring to track regulatory, political, and supply chain risks before they become crises.
This practical guide provides a framework for using FDA Foreign Warning Letters as a proactive intelligence tool for API supply chain monitoring and ensuring compliance with complex drug manufacturing regulations.
This guide offers a practical framework for UK public affairs teams to analyze political party manifestos. Learn a four-step process to deconstruct policy pledges, identify early warnings of regulatory change, and transform political documents into a predictive map of legislative threats and opportunities.
AI-powered automated compliance monitoring is the only scalable solution for SMEs facing complex regulations like CSRD and CSDDD. Move beyond manual spreadsheets to a proactive, intelligent system for managing regulatory risk.
As of May 2026, EU Member States are transposing the CSDDD into national law, creating a fragmented compliance landscape. This guide outlines the current status of CSDDD implementation, highlights key divergences in penalties and liability, and provides a framework for business preparation.
The EU AI Act's compliance deadlines have been updated. This guide provides a clear roadmap to the new AI Act timeline, including the August 2026 transparency rules and the crucial 2027-2028 deadlines for high-risk systems.
A detailed guide to the EU AI Act's high-risk categories. Understand the classification system, the eight use cases in Annex III, and the core compliance requirements to avoid fines of up to €35 million.
Navigate Japan's complex pharmaceutical market with our expert guide. Understand the core challenges of the MHLW-led drug pricing system, key repricing rules like Market Expansion Repricing, and major policy trends to watch.
US pharma faces growing risks from Chinese API dependency. This guide explains why traditional methods fail and outlines a proactive framework for China API export monitoring across regulatory, political, and market signals to protect your supply chain.